BioCryst Pharmaceuticals (BCRX) news
Recent news
BioCryst announces formation of scientific advisory board to
AInvest Wire · Oct 5, 2026BioCrystal Pharmaceuticals, Inc.: RBC cuts to sector perform from outperform; cuts target price to $11 from $13
RBC Capital Markets has revised its recommendation for BioCryst Pharmaceuticals, Inc. (BCRX), downgrading the stock from "outperform" to "sector perform," while also lowering its price target to $11 from $13. The adjustment reflects a reassessment of the company's near-term outlook and market…
AInvest Wire · Sep 10, 2026BioCryst gets Japan nod for Orladeyo in pediatric HAE patients
AInvest Wire · Aug 25, 2026BIOCRYST PHARMACEUTICALS: Cash, cash equivalents, restricted cash and investments $354 mln at June 30, 2026
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that its cash, cash equivalents, restricted cash, and investments totaled $354 million as of June 30 . This represents an increase from the $260.8 million reported at March 31 , and reflects the company’s ongoing financial activities, including…
AInvest Wire · Aug 5, 2026BIOCRYST PHARMACEUTICALS OUTLOOK FY SALES USD 690-715 MILLION
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has demonstrated consistent growth in its flagship product, ORLADEYO, with full-year 2025 net revenue reaching $601.8 million, representing a 38% year-over-year increase . Based on this trajectory and recent updates, the company is now projecting 2026…
AInvest Wire · Aug 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.